Lees verder
Building on the strong foundation of its predecessors Royal Dutch Yeast and Spirit Factory and Royal Gist-brocades, today's, biotechnology competences and expertise rank DSM among the top three companies in the world in industrial biotechnology. 20% of DSM's total sales are derived from biotechnology. DSM's nutrition business, which nowadays represents 70% of DSM's net sales, started in Delft with yeast and enzymes for use in food and beverages.

Biotechnology based solutions will be key to address some of the world’s biggest issues, including climate change, resource scarcity, circularity and enabling healthy nutrition for a fast-growing global population.  Since 1869, many innovations developed at the Delft site have found their way into society including: a production strain and process for the large-scale production of penicillin, a natural antifungal food preservative widely used to protect a variety of foods and beverages from spoilage; and enzymes, which among other things enable the many millions of people worldwide with a lactose intolerance to include nutritious dairy in their diets. Recent innovations from DSM’s facilities in Delft include Veramaris’ algae-derived Omega-3 oil, enabling more sustainable aquaculture and healthier fish for the consumer, and Avansya’s zero-calorie sweetener.

For DSM, biotechnology is an essential pillar for innovation and a driver for growth. To build on the rich heritage of biotechnology in Delft and accelerate biotech innovations between companies and knowledge institutes, DSM recently founded the Biotech Campus Delft, in close collaboration with Delft University of Technology, the municipality of Delft, province of South-Holland and the regional economic development agency InnovationQuarter. This ground-breaking campus in Europe hosts startups, tech- and service-providers, small and medium-sized enterprises and established companies in the field of biotechnology and creates an ecosystem that boosts the transition to a sustainable, bio-based and circular economy. The open innovation campus supports the whole innovation cycle, from research to piloting, and through scale-up to production and commercialization.

Feike Sijbesma, CEO/Chairman DSM Managing Board: “I’m proud of our biotechnology roots in Delft and the economic, environmental and societal value this heritage brings to DSM. The economic and environmental benefits of using micro-organisms, for example yeast, bacteria and algae, to help solve some of the biggest challenges in the world are becoming more and more apparent. Moreover, the social entrepreneurship and drive to take care of people and the society, started by my predecessor Jacques van Marken in 1869, is still an intrinsic part of our company’s culture today, 150 years on.”

Eric Wiebes, Minister of Economic Affairs and Climate Policy: “For already 150 years, DSM and its predecessors have been an economic success in Delft and in the Netherlands. I believe that a key factor for that success is that DSM has always been in transition. This means that DSM embraces innovation and adapts to changing dynamics, both on the market and in society. Over the years there have been many examples of biotechnological innovations from DSM that benefitted the environment. The environmental and climate transition we are currently facing requires even more. This gives DSM the chance to set an example for many others.”